Serious adverse events · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine changes serious adverse events compared with vandetanib (very low certainty).
1 finding from 1 review
Serious adverse events · episodic viral wheeze in children
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · episodic viral wheeze in children
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · School‐aged children and adults
Intermittent ICS showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · Preschool children (<6 years)
Intermittent ICS showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · patients with anaemia
It is very uncertain whether parenteral iron changes serious adverse events compared with inactive control (very low certainty).
1 finding from 1 review
Serious adverse events · patients with anaemia
It is very uncertain whether parenteral iron changes serious adverse events compared with oral iron (very low certainty).
1 finding from 1 review
Serious adverse events · patients with anaemia
It is very uncertain whether oral iron changes serious adverse events compared with inactive control (very low certainty).
1 finding from 1 review
Serious adverse events · Adults and children with uncomplicated P. vivax malaria
Summary of findings: ACT showed no clear difference in serious adverse events compared with CQ (high certainty).
1 finding from 1 review
Serious adverse events · patients with primary CNS lymphoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Serious adverse events · patients with rheumatoid arthritis pain
1 finding from 1 review
Serious adverse events · patients with Shigella dysentery
Cotrimoxazole led to lower serious adverse events compared with furazolidone; GRADE not reported.
1 finding from 1 review
Serious adverse events · patients with initial ART
TDF showed no clear difference in serious adverse events compared with AZT (high certainty).
1 finding from 1 review
Adverse events ‐ Serious adverse events · people with inhibitors
Summary of findings table ‐ Concizumab prophylaxis showed no clear difference in adverse events ‐ Serious adverse events compared with on‐demand therapy (low certainty).
1 finding from 1 review
Adverse events ‐ Serious adverse events · people without inhibitors
Summary of findings table ‐ Fitusiran prophylaxis showed no clear difference in adverse events ‐ Serious adverse events compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
adverse events(6 weeks) · depression in adults
1 finding from 1 review
Allergic adverse events · patients with Helicobacter pylori infection
It is very uncertain whether any antibiotic regimen plus N‐acetylcysteine changes allergic adverse events compared with the same regimen without N‐acetylcysteine (with or without placebo) (very low certainty).
1 finding from 1 review